메뉴 건너뛰기




Volumn 41, Issue 1, 2006, Pages 23-30

Is moderate HIV viremia associated with a higher risk of clinical progression in HIV-infected people treated with highly active antiretroviral therapy: Evidence from the Italian Cohort of Antiretroviral-Naive patients study

Author keywords

Clinical progression; Detectable viremia; Highly active antiretroviral therapy; Viral load set point; Virologic failure

Indexed keywords

ANTIRETROVIRUS AGENT;

EID: 28944437070     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000188337.76164.7a     Document Type: Article
Times cited : (41)

References (31)
  • 2
    • 0033550965 scopus 로고    scopus 로고
    • Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study
    • Lederberger B, Egger M, Opravil M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Lancet. 1999;353:863-868.
    • (1999) Lancet , vol.353 , pp. 863-868
    • Lederberger, B.1    Egger, M.2    Opravil, M.3
  • 3
    • 0345490968 scopus 로고    scopus 로고
    • HIV-1-infected antiretroviral-treated patients with prolonged partial viral suppression
    • Tenorio AR, Smith KY, Kuritzkes DR, et al. HIV-1-infected antiretroviral-treated patients with prolonged partial viral suppression. J Acquir Immune Defic Syndr. 2003;34:491-496.
    • (2003) J Acquir Immune Defic Syndr , vol.34 , pp. 491-496
    • Tenorio, A.R.1    Smith, K.Y.2    Kuritzkes, D.R.3
  • 4
    • 0034070773 scopus 로고    scopus 로고
    • Sustained CD4+ T cell response after virological failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection
    • Deeks SG, Barbour JD, Martin JN, et al. Sustained CD4+ T cell response after virological failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection. J Infect Dis. 2000;181:946-953.
    • (2000) J Infect Dis , vol.181 , pp. 946-953
    • Deeks, S.G.1    Barbour, J.D.2    Martin, J.N.3
  • 5
    • 0041326880 scopus 로고    scopus 로고
    • Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy
    • Hunt PW, Deeks SG, Rodriguez B, et al. Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy. AIDS. 2003;17:1907-1915.
    • (2003) AIDS , vol.17 , pp. 1907-1915
    • Hunt, P.W.1    Deeks, S.G.2    Rodriguez, B.3
  • 6
    • 0037692997 scopus 로고    scopus 로고
    • Changes in viral load in people with virological failure who remain on the same HAART regimen
    • Cozzi Lepri A, Phillips AN, Miller V, et al. Changes in viral load in people with virological failure who remain on the same HAART regimen. Antiviral Ther. 2003;8:127-136.
    • (2003) Antiviral Ther , vol.8 , pp. 127-136
    • Cozzi Lepri, A.1    Phillips, A.N.2    Miller, V.3
  • 7
    • 3042740596 scopus 로고    scopus 로고
    • Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes
    • The PLATO Collaboration. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet. 2004;364:51-62.
    • (2004) Lancet , vol.364 , pp. 51-62
  • 8
    • 9144231780 scopus 로고    scopus 로고
    • Strong cell-mediated immune responses are associated with the maintenance of low-level viremia in antiretroviral-treated individuals with drug-resistant human immunodeficiency virus type 1
    • Deeks SG, Martin JN, Sinclair E, et al. Strong cell-mediated immune responses are associated with the maintenance of low-level viremia in antiretroviral-treated individuals with drug-resistant human immunodeficiency virus type 1. J Infect Dis. 2004;189:312-321.
    • (2004) J Infect Dis , vol.189 , pp. 312-321
    • Deeks, S.G.1    Martin, J.N.2    Sinclair, E.3
  • 9
    • 0033790674 scopus 로고    scopus 로고
    • The impact of protease inhibitor-containing highly active antiretroviral therapy on progression of HIV disease and its relationship to CD4 and viral load
    • Miller V, Sabin CA, Phillips AN, et al. The impact of protease inhibitor-containing highly active antiretroviral therapy on progression of HIV disease and its relationship to CD4 and viral load. AIDS. 2000;14:2129-2136.
    • (2000) AIDS , vol.14 , pp. 2129-2136
    • Miller, V.1    Sabin, C.A.2    Phillips, A.N.3
  • 10
    • 4444282188 scopus 로고    scopus 로고
    • Effect of persistent moderate viremia on disease progression during HIV therapy
    • Raffanti SP, Fusco JS, Sherrill BH, et al. Effect of persistent moderate viremia on disease progression during HIV therapy. J Acquir Immune Defic Syndr. 2004;37:1147-1154.
    • (2004) J Acquir Immune Defic Syndr , vol.37 , pp. 1147-1154
    • Raffanti, S.P.1    Fusco, J.S.2    Sherrill, B.H.3
  • 11
    • 0242529051 scopus 로고    scopus 로고
    • Insight into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients
    • d'Arminio Monforte A, Cozzi Lepri A, Rezza G, et al. Insight into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. AIDS. 2000;14:499-507.
    • (2000) AIDS , vol.14 , pp. 499-507
    • D'Arminio Monforte, A.1    Cozzi Lepri, A.2    Rezza, G.3
  • 12
    • 0027122957 scopus 로고
    • 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults
    • Centers for Disease Control and Prevention. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR. 1992;41:1-19.
    • (1992) MMWR , vol.41 , pp. 1-19
  • 13
    • 20544443261 scopus 로고    scopus 로고
    • Update of the drug resistance mutations in HIV-1: 2005
    • Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: 2005. Top HIV Med. 2005;13:51-57. Available at: http://www.iasusa.org/resistance_mutations/. Accessed June 2005.
    • (2005) Top HIV Med , vol.13 , pp. 51-57
    • Johnson, V.A.1    Brun-Vezinet, F.2    Clotet, B.3
  • 14
    • 0034687071 scopus 로고    scopus 로고
    • Clinical outcome of patients with HIV-1 infection according to immunological and virologic response after 6 months of highly active antiretroviral therapy
    • Grabar S, Le Moing V, Goujard C, et al. Clinical outcome of patients with HIV-1 infection according to immunological and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med. 2000;133:401-410.
    • (2000) Ann Intern Med , vol.133 , pp. 401-410
    • Grabar, S.1    Le Moing, V.2    Goujard, C.3
  • 15
    • 0037013040 scopus 로고    scopus 로고
    • Drug resistance at low viraemia in HIV-1-infected patients with antiretroviral combination therapy
    • Aleman S, Soderbarg K, Visco-Comandini V, et al. Drug resistance at low viraemia in HIV-1-infected patients with antiretroviral combination therapy. AIDS. 2002;16:1039-1044.
    • (2002) AIDS , vol.16 , pp. 1039-1044
    • Aleman, S.1    Soderbarg, K.2    Visco-Comandini, V.3
  • 16
    • 0032492398 scopus 로고    scopus 로고
    • CD4 cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART)
    • Kauffman D. CD4 cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Lancet. 1998;351:723-724.
    • (1998) Lancet , vol.351 , pp. 723-724
    • Kauffman, D.1
  • 17
    • 0037083230 scopus 로고    scopus 로고
    • Predictors of long-term increase in CD4(+) cell counts in human immunodeficiency virus-infected patients receiving a protease inhibitor-containing antiretroviral regimen
    • Le Moing V, Thiebaut R, Chene G, et al. Predictors of long-term increase in CD4(+) cell counts in human immunodeficiency virus-infected patients receiving a protease inhibitor-containing antiretroviral regimen. J Infect Dis. 2002;185:471-480.
    • (2002) J Infect Dis , vol.185 , pp. 471-480
    • Le Moing, V.1    Thiebaut, R.2    Chene, G.3
  • 18
    • 0032928065 scopus 로고    scopus 로고
    • Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1
    • Martinez-Picado J, Savara AV, Sutton L, et al. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1. J Virol. 1999;73:3744-3752.
    • (1999) J Virol , vol.73 , pp. 3744-3752
    • Martinez-Picado, J.1    Savara, A.V.2    Sutton, L.3
  • 19
    • 0034948377 scopus 로고    scopus 로고
    • Impaired replication of protease inhibitor-resistant HIV-1 in human thymus
    • Stoddart C, Liegler TJ, Mammano F, et al. Impaired replication of protease inhibitor-resistant HIV-1 in human thymus. Nat Med. 2001;7:712-718.
    • (2001) Nat Med , vol.7 , pp. 712-718
    • Stoddart, C.1    Liegler, T.J.2    Mammano, F.3
  • 20
    • 9544225179 scopus 로고    scopus 로고
    • Apoptosis mediated by HIV protease is preceded by the cleavage of Bcl-2
    • Strack PR, Frey MW, Rizzo CJ, et al. Apoptosis mediated by HIV protease is preceded by the cleavage of Bcl-2. Proc Natl Acad Sci USA. 1996;93:9571-9576.
    • (1996) Proc Natl Acad Sci USA , vol.93 , pp. 9571-9576
    • Strack, P.R.1    Frey, M.W.2    Rizzo, C.J.3
  • 21
    • 19944427724 scopus 로고    scopus 로고
    • Persistent low viral load on antiretroviral therapy is associated with T cell-mediated control of HIV replication
    • Alatrakchi N, Duvivier C, Costagliola D, et al. Persistent low viral load on antiretroviral therapy is associated with T cell-mediated control of HIV replication. AIDS. 2005;19:25-33.
    • (2005) AIDS , vol.19 , pp. 25-33
    • Alatrakchi, N.1    Duvivier, C.2    Costagliola, D.3
  • 22
    • 0028943992 scopus 로고
    • In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors
    • Condra JH, Schleif WA, Blahy OM, et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature. 1995;374:569-571.
    • (1995) Nature , vol.374 , pp. 569-571
    • Condra, J.H.1    Schleif, W.A.2    Blahy, O.M.3
  • 23
    • 15444377672 scopus 로고    scopus 로고
    • Ordered accumulation of mutations in HIV protease confers resistance to ritonavir
    • Molla A, Korneyeva M, Gao Q, et al. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med. 1996;2:760-766.
    • (1996) Nat Med , vol.2 , pp. 760-766
    • Molla, A.1    Korneyeva, M.2    Gao, Q.3
  • 24
    • 3843061223 scopus 로고    scopus 로고
    • Evolution of resistance to drugs in HIV-1-infected patients failing antiretroviral therapy
    • Kantor R, Shafer RW, Follansbee S, et al. Evolution of resistance to drugs in HIV-1-infected patients failing antiretroviral therapy. AIDS. 2004;18:1503-1511.
    • (2004) AIDS , vol.18 , pp. 1503-1511
    • Kantor, R.1    Shafer, R.W.2    Follansbee, S.3
  • 25
    • 0035477944 scopus 로고    scopus 로고
    • Transient relapses ("blips") of plasma HIV RNA levels during HAART are associated with drug resistance
    • Cohen Stuart JW, Wensing AM, Kovacs C, et al. Transient relapses ("blips") of plasma HIV RNA levels during HAART are associated with drug resistance. J Acquir Immune Defic Syndr. 2001;28:105-113.
    • (2001) J Acquir Immune Defic Syndr , vol.28 , pp. 105-113
    • Cohen Stuart, J.W.1    Wensing, A.M.2    Kovacs, C.3
  • 26
    • 0029028067 scopus 로고
    • Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy
    • Larder BA, Kemp SD, Harrigan PR. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science. 1995;269:696-699.
    • (1995) Science , vol.269 , pp. 696-699
    • Larder, B.A.1    Kemp, S.D.2    Harrigan, P.R.3
  • 27
    • 3242683096 scopus 로고    scopus 로고
    • Antiretroviral resistance among HIV-infected persons who have died in British Columbia, in the era of modern antiretroviral therapy
    • Recsky MA, Brumme ZL, Chan KJ, et al. Antiretroviral resistance among HIV-infected persons who have died in British Columbia, in the era of modern antiretroviral therapy. J Infect Dis. 2004;190:285-292.
    • (2004) J Infect Dis , vol.190 , pp. 285-292
    • Recsky, M.A.1    Brumme, Z.L.2    Chan, K.J.3
  • 28
    • 0032804864 scopus 로고    scopus 로고
    • Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy
    • Nijhuis M, Schuurman R, de Jong D, et al. Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. AIDS. 1999;13:2349-2359.
    • (1999) AIDS , vol.13 , pp. 2349-2359
    • Nijhuis, M.1    Schuurman, R.2    De Jong, D.3
  • 29
    • 2342591920 scopus 로고    scopus 로고
    • Immunologic and virologic evolution during periods of intermittent and persistent low-level viremia
    • Karlsson AC, Younger SR, Martin JN, et al. Immunologic and virologic evolution during periods of intermittent and persistent low-level viremia. AIDS. 2004;18:981-989.
    • (2004) AIDS , vol.18 , pp. 981-989
    • Karlsson, A.C.1    Younger, S.R.2    Martin, J.N.3
  • 30
    • 20144370827 scopus 로고    scopus 로고
    • Interruption of highly active antiretroviral therapy in HIV clinical practice: Results from the ICoNA study
    • D'Arminio Monforte A, Cozzi Lepri A, Phillips A, et al. Interruption of highly active antiretroviral therapy in HIV clinical practice: results from the ICoNA study. J Acquir Immune Defic Syndr. 2005;38:407-416.
    • (2005) J Acquir Immune Defic Syndr , vol.38 , pp. 407-416
    • D'Arminio Monforte, A.1    Cozzi Lepri, A.2    Phillips, A.3
  • 31
    • 0037169269 scopus 로고    scopus 로고
    • Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia
    • Deeks SG, Barbour JD, Grant RM, et al. Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia. AIDS. 2002;16:201-207.
    • (2002) AIDS , vol.16 , pp. 201-207
    • Deeks, S.G.1    Barbour, J.D.2    Grant, R.M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.